S
Susan Wang
Researcher at Boehringer Ingelheim
Publications - 4
Citations - 10833
Susan Wang is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Dabigatran & Stroke. The author has an hindex of 4, co-authored 4 publications receiving 9956 citations.
Papers
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Paul A. Reilly,Thorsten Lehr,Sebastian Haertter,Stuart J. Connolly,Salim Yusuf,John W. Eikelboom,Michael D. Ezekowitz,Gerhard Nehmiz,Susan Wang,Lars Wallentin +9 more
TL;DR: Individual benefit-risk might be improved by tailoring dabigatran dose after considering selected patient characteristics, and the risk of ischemic stroke and bleeding outcomes were correlated with dabig atran plasma concentrations.
Journal ArticleDOI
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Michael D. Ezekowitz,Stuart J. Connolly,Amit Parekh,Paul A. Reilly,Jeanne Varrone,Susan Wang,Jonas Oldgren,Ellison Themeles,Lars Wallentin,Salim Yusuf +9 more
TL;DR: The RE-LY trial is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs, and the worldwide site distribution and broad range of stroke risk further increase the general applicability.
Journal Article
Re-Ly study of stroke prevention in atrial fibrillation Dabigatren versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361.10: 1056
Stuart J. Connolly,Michael D. Ezekowitz,Salim Yusuf,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +19 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 1110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major haemorrhage.